Progenics Pharmaceuticals, Inc. is now a
subsidiary of Lantheus Holdings, Inc.

About Progenics

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (PSMA) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has three commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which are partnered with Bausch Health Companies Inc.

Progenics is proud to have joined the Lantheus family. Lantheus, a global leader in the field of medical imaging, develops, manufactures and commercializes essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.

Learn more

Product Pipeline


pipeline-homepage

Our pipeline includes drug candidates in all stages of development. See All